459 related articles for article (PubMed ID: 30519476)
1. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.
Poirier A; Weetall M; Heinig K; Bucheli F; Schoenlein K; Alsenz J; Bassett S; Ullah M; Senn C; Ratni H; Naryshkin N; Paushkin S; Mueller L
Pharmacol Res Perspect; 2018 Dec; 6(6):e00447. PubMed ID: 30519476
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
Sturm S; Günther A; Jaber B; Jordan P; Al Kotbi N; Parkar N; Cleary Y; Frances N; Bergauer T; Heinig K; Kletzl H; Marquet A; Ratni H; Poirier A; Müller L; Czech C; Khwaja O
Br J Clin Pharmacol; 2019 Jan; 85(1):181-193. PubMed ID: 30302786
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).
Ratni H; Ebeling M; Baird J; Bendels S; Bylund J; Chen KS; Denk N; Feng Z; Green L; Guerard M; Jablonski P; Jacobsen B; Khwaja O; Kletzl H; Ko CP; Kustermann S; Marquet A; Metzger F; Mueller B; Naryshkin NA; Paushkin SV; Pinard E; Poirier A; Reutlinger M; Weetall M; Zeller A; Zhao X; Mueller L
J Med Chem; 2018 Aug; 61(15):6501-6517. PubMed ID: 30044619
[TBL] [Abstract][Full Text] [Related]
4. Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).
Markati T; Fisher G; Ramdas S; Servais L
Expert Opin Investig Drugs; 2022 May; 31(5):451-461. PubMed ID: 35316106
[TBL] [Abstract][Full Text] [Related]
5. [Risdiplam for the treatment of spinal muscular atrophy].
Vlodavets DV
Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy.
Zhao X; Feng Z; Ling KK; Mollin A; Sheedy J; Yeh S; Petruska J; Narasimhan J; Dakka A; Welch EM; Karp G; Chen KS; Metzger F; Ratni H; Lotti F; Tisdale S; Naryshkin NA; Pellizzoni L; Paushkin S; Ko CP; Weetall M
Hum Mol Genet; 2016 May; 25(10):1885-1899. PubMed ID: 26931466
[TBL] [Abstract][Full Text] [Related]
7. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
Kletzl H; Marquet A; Günther A; Tang W; Heuberger J; Groeneveld GJ; Birkhoff W; Mercuri E; Lochmüller H; Wood C; Fischer D; Gerlach I; Heinig K; Bugawan T; Dziadek S; Kinch R; Czech C; Khwaja O
Neuromuscul Disord; 2019 Jan; 29(1):21-29. PubMed ID: 30553700
[TBL] [Abstract][Full Text] [Related]
8. Risdiplam in Type 1 Spinal Muscular Atrophy.
Baranello G; Darras BT; Day JW; Deconinck N; Klein A; Masson R; Mercuri E; Rose K; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Seabrook T; Fontoura P; Servais L;
N Engl J Med; 2021 Mar; 384(10):915-923. PubMed ID: 33626251
[TBL] [Abstract][Full Text] [Related]
9. Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment.
Mercuri E; Baranello G; Boespflug-Tanguy O; De Waele L; Goemans N; Kirschner J; Masson R; Mazzone ES; Pechmann A; Pera MC; Vuillerot C; Bader-Weder S; Gerber M; Gorni K; Hoffart J; Kletzl H; Martin C; McIver T; Scalco RS; Yeung WY; Servais L;
Eur J Neurol; 2023 Jul; 30(7):1945-1956. PubMed ID: 35837793
[TBL] [Abstract][Full Text] [Related]
10. Risdiplam: First Approval.
Dhillon S
Drugs; 2020 Nov; 80(17):1853-1858. PubMed ID: 33044711
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy.
Ando S; Suzuki S; Okubo S; Ohuchi K; Takahashi K; Nakamura S; Shimazawa M; Fuji K; Hara H
Sci Rep; 2020 Oct; 10(1):17472. PubMed ID: 33060681
[TBL] [Abstract][Full Text] [Related]
12. SMN protein is required throughout life to prevent spinal muscular atrophy disease progression.
Zhao X; Feng Z; Risher N; Mollin A; Sheedy J; Ling KKY; Narasimhan J; Dakka A; Baird JD; Ratni H; Lutz C; Chen KS; Naryshkin NA; Ko CP; Welch E; Metzger F; Weetall M
Hum Mol Genet; 2021 Dec; 31(1):82-96. PubMed ID: 34368854
[TBL] [Abstract][Full Text] [Related]
13. Risdiplam: A Review in Spinal Muscular Atrophy.
Paik J
CNS Drugs; 2022 Apr; 36(4):401-410. PubMed ID: 35284988
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.
Feng Z; Ling KK; Zhao X; Zhou C; Karp G; Welch EM; Naryshkin N; Ratni H; Chen KS; Metzger F; Paushkin S; Weetall M; Ko CP
Hum Mol Genet; 2016 Mar; 25(5):964-75. PubMed ID: 26758873
[TBL] [Abstract][Full Text] [Related]
15. Recognition of single-stranded nucleic acids by small-molecule splicing modulators.
Tang Z; Akhter S; Ramprasad A; Wang X; Reibarkh M; Wang J; Aryal S; Thota SS; Zhao J; Douglas JT; Gao P; Holmstrom ED; Miao Y; Wang J
Nucleic Acids Res; 2021 Aug; 49(14):7870-7883. PubMed ID: 34283224
[TBL] [Abstract][Full Text] [Related]
16. Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the
Fowler S; Brink A; Cleary Y; Günther A; Heinig K; Husser C; Kletzl H; Kratochwil N; Mueller L; Savage M; Stillhart C; Tuerck D; Ullah M; Umehara K; Poirier A
Drug Metab Dispos; 2022 Jan; 50(1):65-75. PubMed ID: 34620695
[TBL] [Abstract][Full Text] [Related]
17. In brief: Risdiplam (Evrysdi) for spinal muscular atrophy.
Med Lett Drugs Ther; 2021 Jul; 63(1629):e1-e2. PubMed ID: 34544108
[No Abstract] [Full Text] [Related]
18. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
[TBL] [Abstract][Full Text] [Related]
19. Real-world evidence: Risdiplam in a patient with spinal muscular atrophy type I with a novel splicing mutation and one SMN2 copy.
Ma K; Zhang K; Chen D; Wang C; Abdalla M; Zhang H; Tian R; Liu Y; Song L; Zhang X; Liu F; Liu G; Wang D
Hum Mol Genet; 2024 Jun; 33(13):1120-1130. PubMed ID: 38520738
[TBL] [Abstract][Full Text] [Related]
20. Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy.
Cleary Y; Gertz M; Grimsey P; Günther A; Heinig K; Ogungbenro K; Aarons L; Galetin A; Kletzl H
Clin Pharmacol Ther; 2021 Dec; 110(6):1547-1557. PubMed ID: 34347881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
